Knockdown of p53 in NT2/D1 and NT2/D1-R1 cells resulted in relative guadecitabine resistance which demonstrates that activation of p53 is important for guadecitabine sensitivity of testicular cancer cells (Figure 7A and 7B). Here, TP53 is linked to testicular cancer.